The Lesion Analysis/ Biostatistics Core will continue to provide support to each of the three projects in study design and assessment of atherosclerotic lesion development. The Core ensures consistent quantitative and qualitative assessment of atherosclerotic lesions, adequately powered experimental design and appropriate analysis of experimental results across all three projects of the PPG. Specifically, the Core will provide state-of-the-art expertise in A) quantification of atherosclerotic lesions; B) qualitative assessment of lesion composition; C) apoptosis and in situ efferocytosis assays; D) markers of cell adhesion and inflammation; E) laser-capture microdissection (LCM) for cell-specific quantitative gene expression analyses; and F) biostatistical support including study design and power analyses. In addition, the Core will provide biostatistical support for genome-wide transcriptomic and chromatin analyses via the expertise of Dr. Ying Wei, Professor of Biostatistics.
Core A ? Narrative A recent public health report by the Centers of Disease Control indicated that, for the first in decades, deaths from heart disease and incidence of stroke are increasing while life expectancy is decreasing in the US. An obesity epidemic is driving the increased incidence of diabetes and coronary heart disease. Core A provides expertise and consistency in the quantitative and qualitative assessment of atherosclerosis, the major disease underlying CHD in humans, and statistical support for genomic approaches to understand the link between obesity, insulin resistance and atherosclerosis.
Showing the most recent 10 out of 98 publications
